3B BlackBio Q1 FY27 Net Profit Rises 89.6% YoY

Key Decisions and Approvals

1. Financial Results Approval

The Board of Directors approved the unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 (Q1 FY27). The Audit Committee reviewed these results in its meeting held on the same date.

Baheti & Co., Statutory Auditors of the Company, carried out a Limited Review of both Standalone and Consolidated Financial Results for the quarter. The Board took on record their Limited Review Reports, which contained no modifications or qualifications.

2. Appointment of Cost Auditor

The Board appointed M/s Sanjay Kasliwal & Associates, Cost Accountants & Social Auditor, Bhopal, as Cost Auditor for FY 2026-27. This appointment complies with Section 148 of the Companies Act, 2013 and Companies (Cost Records and Audit) Rules, 2014.

The remuneration payable to M/s Sanjay Kasliwal & Associates will be placed before shareholders for ratification at the ensuing Annual General Meeting.

Financial Performance Highlights (Standalone)

Quarter Ended June 30, 2026 (Q1 FY27)

Revenue from operations: ₹2,824.79 lakh
Other income: ₹614.30 lakh
Total Income: ₹3,439.09 lakh
Profit before tax: ₹1,835.32 lakh
Current tax expense: ₹424.11 lakh
Deferred tax expense: ₹0.00 lakh
Profit for the period: ₹1,411.21 lakh
Paid-up Equity Share capital: ₹856.84 lakh
Reserves: ₹26,421.76 lakh (excluding Revaluation Reserves)
Basic EPS: ₹16.47
Diluted EPS: ₹16.47

Comparative Performance (Standalone)

| Basic EPS | ₹16.47 | ₹8.69 | ₹14.54 | ₹57.56 |

Financial Performance Highlights (Consolidated)

Quarter Ended June 30, 2026 (Q1 FY27)

Revenue from operations: ₹3,543.41 lakh
Other income: ₹431.66 lakh
Total Income: ₹3,975.07 lakh
Profit before tax: ₹1,321.95 lakh
Current tax expense: ₹395.64 lakh
Deferred tax expense: ₹88.50 lakh
Profit for the period: ₹897.84 lakh
Profit attributable to owners: ₹955.51 lakh
Profit attributable to non-controlling interests: ₹-55.35 lakh
Paid-up Equity Share capital: ₹856.84 lakh
Reserves: ₹26,243.65 lakh (excluding Revaluation Reserves)
Basic EPS: ₹11.44
Diluted EPS: ₹11.44

Segment-wise Performance (Consolidated)

The Company has two reportable business segments: Agrochemical and Molecular Diagnostic Kits (Health Care Sector).

Quarter Ended June 30, 2026:

Agrochemicals Segment Profit: ₹0.03 lakh
Diagnostic Kits Segment Profit: ₹1,332.16 lakh
Total Segment Profit before Interest and Tax: ₹1,332.19 lakh
Interest Expense: ₹10.22 lakh
Agrochemicals Interest: ₹0.02 lakh
Diagnostic Kits Interest: ₹10.22 lakh

Important Notes and Qualifications

1. Business Seasonality: The Company's Agrochemical Business is seasonal and performance can be impacted by weather conditions and cropping patterns.

2. Accounting Standards: Financial results prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of Companies Act, 2013.

3. Quarterly Figures: Figures for quarter ended March 31, 2026 are balancing figures between audited annual figures and unaudited nine-month figures.

4. Rounding Off: All financial figures rounded off to nearest lakh in rupees.

5. Other Expenses Increase: 30% increase in other expenses mainly due to expenditure incurred towards IVDR regulatory registration process and participation in international trade fair.

6. Subsidiaries Included: Consolidated financials include results of:

TRUPCR Europe Limited (Subsidiary)
Coris Holding, SRL, Belgium (Subsidiary)

7. Limited Review Completion: The limited review required under Regulation 33 of SEBI LODR has been completed with no impact on the reported results.

Meeting Details

Date: August 13, 2026
Time: 3:00 PM to 3:50 PM
Venue: Not specified (document signed in Bhopal)